Saturday, January 11, 2020 12:59:25 PM
LCTX states
"We have entered into three separate agreements with entities in the cell therapy space for the license, development, manufacture and sale of products based on our broad cell therapy platform and technologies."
Subsequently on 12/30 AgeX states...
" Going forward we plan to strengthen our capacity of executing on external licensing and collaboration deals with third parties as well as in-house cell therapy product development."
Does anyone have a clear idea or a website that explains who is selling what? When AgeX split from BTX/LCTX who owns the rights to which patents, etc.?
Any clarification would be greatly appreciated.
NOTE: I'm posting this on both the LCTX and the AgeX sites.
Recent AGE News
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results • GlobeNewswire Inc. • 03/22/2024 09:27:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:47:08 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/07/2024 12:47:43 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:01:43 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2024 05:15:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:05:20 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/05/2024 12:19:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:05:39 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/17/2024 09:19:13 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 01/16/2024 02:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:05:36 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/09/2024 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:02:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:25:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 10:11:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:05:38 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/16/2023 09:01:20 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/15/2023 02:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:25:21 PM
- AgeX Therapeutics Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM